If you have been tracking sava stock (Cassava Sciences, Inc.) over the past few years, you already know it was one of the most polarizing and volatile plays in the entire biotechnology sector. Retail investors rallied around its promise of a revolutionary Alzheimer’s disease treatment, while short-sellers and regulators scrutinized its scientific integrity. Today, however, the landscape has completely shifted. In March 2026, Cassava Sciences underwent a dramatic transformation—officially rebranding as Filana Therapeutics, Inc. and changing its ticker symbol from SAVA to FLNA on the Nasdaq.

If you are searching for the latest sava stock news, you must understand that the old thesis is officially dead. The company has terminated its Alzheimer’s program and is now mounting a high-stakes pivot to rare pediatric epilepsy. This comprehensive, expert-led guide will walk you through the complete demise of the Alzheimer’s clinical trials, the scientific details of their new epilepsy play, the resolution of their long-standing legal battles, and whether FLNA stock is a speculative buy or a cash-burning gamble to avoid.

The Fall of the Alzheimer’s Hypothesis: What Happened to Simufilam?

For years, SAVA stock traded entirely on the clinical progress of its lead drug candidate, simufilam (previously known as PTI-125). Simufilam was designed as an oral small molecule targeting an altered form of a scaffolding protein in the brain called filamin A (FLNA). The theory was that restoring the normal shape and function of filamin A would disrupt the toxic signaling cascade of soluble amyloid beta-42 via alpha-7 nicotinic acetylcholine receptors, thereby reducing neurodegeneration and neuroinflammation.

However, the scientific foundation of this hypothesis came under intense fire. Critics, whistleblowers, and short-sellers accused the company and its academic collaborators of data manipulation, leading to FDA citizen petitions, SEC charges, and a Department of Justice (DOJ) criminal investigation.

The heart of the controversy focused on Dr. Hoau-Yan Wang, a prominent researcher whose laboratory at the City University of New York (CUNY) collaborated extensively with Cassava Sciences. The allegations focused on western blot images—a laboratory technique used to detect specific proteins in tissue samples. Critics argued that images in multiple peer-reviewed papers published by Dr. Wang and Cassava executives showed signs of digital manipulation, such as splicing, duplication, and altered background noise. These images were used to prove that simufilam effectively binds to filamin A and restores its shape.

When these papers were called into question, short-sellers seized on the discrepancy, publishing detailed dossiers on scientific forums like PubPeer. The resulting storm led CUNY to conduct an internal investigation, which ultimately concluded that there were numerous instances of research misconduct. This finding laid the groundwork for the SEC civil charges and the DOJ criminal indictment of Dr. Wang. Although the DOJ eventually dismissed Dr. Wang's indictment with prejudice in October 2025, the reputational damage to Cassava's scientific credibility was already done. Despite the noise, Cassava pushed forward into massive Phase 3 clinical trials: RETHINK-ALZ and REFOCUS-ALZ.

The house of cards collapsed in late 2024:

• The RETHINK-ALZ Crash: On November 25, 2024, Cassava announced that the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease failed to meet any of its co-primary, secondary, or exploratory biomarker endpoints. The co-primary endpoints—measured after one year of treatment—were changes in cognition (measured by the Alzheimer's Disease Assessment Scale–Cognitive Subscale, or ADAS-Cog12) and daily function (measured by the Alzheimer's Disease Cooperative Study–Activities of Daily Living, or ADCS-ADL). The results were devastating: patients on simufilam performed no better than those on a placebo.
• The Specific Trial Metrics: On the ADAS-Cog12 scale (where lower numbers mean less cognitive impairment), scores rose by 2.8 points on simufilam and 3.2 points on placebo (a statistically insignificant p-value of 0.43). On the ADCS-ADL scale (where higher numbers mean less functional impairment), scores fell by 3.3 points on simufilam and 3.8 points on placebo (another statistically insignificant p-value of 0.40).
• The Market Reaction: Upon the news, SAVA stock plummeted by over 85% in premarket trading, crashing from a close of $26.48 to under $4.00, wiping out billions of dollars in market capitalization in a matter of hours.
• The REFOCUS-ALZ Termination: Given the RETHINK data, Cassava immediately pulled the plug on the second, larger Phase 3 trial (REFOCUS-ALZ) and its open-label extension studies, effectively killing the Alzheimer's program.
• The Post-Mortem Publication: In January 2026, the detailed, peer-reviewed data from these trials were published in the Journal of Prevention of Alzheimer's Disease (JPAD). The publication confirmed that neither the 52-week RETHINK-ALZ (804 patients) nor the 76-week REFOCUS-ALZ (1,125 patients) trial met pre-specified endpoints. While a post-hoc exploratory analysis hinted at potential mild treatment differences in highly specific, localized subgroups of mild patients, the scientific consensus was clear: simufilam was not a viable therapeutic for Alzheimer's disease.

The Rebrand to Filana Therapeutics (NASDAQ: FLNA)

Following the clinical failure, the company's executive team faced a stark reality. The name "Cassava Sciences" had become synonymous with biotech volatility, retail investor controversy, and regulatory investigations. To survive, the company needed to shed its past and present a clean slate to institutional investors.

On March 10, 2026, the company officially rebranded as Filana Therapeutics, Inc. and moved its Nasdaq listing to trade under the ticker FLNA starting March 11, 2026.

According to CEO Rick Barry, who stepped in following the resignation of co-founder Remi Barbier in July 2024, the new name centers the company’s identity on "filamin A" (the FLNA protein). The corporate restructuring was accompanied by a modernized set of bylaws and a newly designed website (filanatx.com). Under the transition to Filana Therapeutics, the company has also sought to bolster its scientific foundation by licensing additional intellectual property. In February 2025, the company licensed additional worldwide rights from Yale University for technologies related to filamin A modulation. This agreement, which carries up to $4.5 million in developmental milestones plus low-to-mid-single digit royalties and minimum annual payments, was a deliberate attempt by management to show that their science is backed by Ivy League research, rather than solely relying on the discredited CUNY publications.

However, a name change does not erase history; the core asset remains the exact same small molecule—simufilam—which is now being redeployed for a vastly different therapeutic target.

The Pivot: Targeting TSC-Related Epilepsy and the FDA Clinical Hold

With Alzheimer's completely out of the picture, Filana's survival depends on demonstrating that simufilam can treat other central nervous system (CNS) disorders. The company’s primary target is now Tuberous Sclerosis Complex (TSC)-related epilepsy.

What is Tuberous Sclerosis Complex (TSC)?

TSC is a rare genetic disorder caused by mutations in the TSC1 or TSC2 genes. These mutations hyperactivate the mechanistic target of rapamycin (mTOR) pathway, leading to non-cancerous tumors growing in multiple organs, including the brain. This genetic disruption results in severe neurological symptoms, particularly intractable, treatment-resistant epilepsy. Approximately 80% to 90% of individuals with TSC suffer from lifelong seizures, and about two-thirds of these patients are refractory (unresponsive) to existing anti-seizure medications.

The Preclinical Rationale

Filana's pivot is backed by preclinical studies conducted in partnership with the TSC Alliance and the TSC Preclinical Consortium. In research published in Science Translational Medicine and presented at medical conferences in late 2025, researchers demonstrated that expression of the actin-crosslinking protein filamin A is significantly increased in brain tissues of patients and mouse models with TSC.

In mouse models (specifically, Tsc1 conditional knockout mice), treatment with simufilam was shown to:

• Alleviate neuronal cytomegaly (abnormal cell enlargement)
• Attenuate the progression of seizure activity
• Demonstrate a statistically significant correlation between drug dose and a reduction in the number of seizures.

The FDA Clinical Hold: A Major Roadblock

Armed with this preclinical data, the company submitted an Investigational New Drug (IND) application to the FDA to initiate a proof-of-concept clinical trial in the first half of 2026.

However, regulatory friction quickly returned. On December 15, 2025, the FDA placed a full clinical hold on the proposed proof-of-concept study. In a formal letter received by the company, the FDA stated that the trial could not proceed until Filana provided additional preclinical safety and toxicity data and modified the clinical protocol design.

This clinical hold was a major blow to investor sentiment, driving SAVA stock (at the time) down another 25% to around $2.13. A clinical hold is an order issued by the FDA to delay or suspend a clinical investigation. In this case, the FDA’s letter demanded additional preclinical toxicity studies in rodents or non-human primates to ensure that the dosages proposed for the epilepsy trial are safe. Specifically, the regulatory agency wants to see more data on the long-term systemic effects of simufilam at higher doses, given that epilepsy treatments often require lifelong administration.

Furthermore, the FDA requested changes to the trial protocol design, such as tighter patient enrollment criteria, more rigorous safety monitoring protocols, and clearer definition of seizure frequency baselines. Because epilepsy trials require highly precise tracking of seizure diaries, any ambiguity in the protocol could lead to uninterpretable data. The hold officially delayed the trial’s start date indefinitely. The company is currently working to resolve the FDA’s concerns, but clinical initiation is heavily dependent on when the agency reviews and accepts the amended protocol—pushing meaningful clinical readouts well into late 2026 or 2027.

Clearing the Legal Fog: DOJ Probes and SEC Settlements

One of the most significant arguments against buying sava stock in the past was the immense legal and regulatory risk. At one point, the company was fighting battles on three distinct fronts: criminal allegations, civil fraud charges, and massive shareholder class-action lawsuits. By mid-2026, much of this legal overhang has finally been resolved, though at an incredibly high financial cost.

1. The Closure of the DOJ Investigation (February 2026)

On February 19, 2026, the company announced that the Fraud Section of the U.S. Department of Justice (DOJ) had officially closed its inquiry into the company regarding allegations of research misconduct. This probe had been triggered by the high-profile indictment of Dr. Hoau-Yan Wang, which was dismissed with prejudice by the DOJ on October 23, 2025. The closure of the inquiry meant that Filana Therapeutics was officially cleared of criminal prosecution by the DOJ.

2. The SEC Settlement (September 2024)

To resolve allegations that it made misleading public statements regarding its Phase 2b clinical trial data, the company reached a settlement with the SEC in September 2024. The company agreed to pay a $40 million civil penalty without admitting or denying the regulator's findings. Former executives Remi Barbier and Lindsay Burns also paid individual fines of $175,000 and $85,000, respectively, while Dr. Wang agreed to a $50,000 penalty.

3. The Class-Action Securities Litigation Settlement (December 2025)

On December 23, 2025, the company announced a definitive agreement to settle the consolidated securities class-action litigation (In re Cassava Sciences) for $31.25 million. The lawsuit sought damages on behalf of investors who purchased SAVA stock or options between September 2020 and October 2023. This settlement resolved all claims tied to allegations of misleading disclosures without the company admitting fault. The $31.25 million loss contingency was fully reserved in the company’s Q2 2025 financial statements, meaning it will not result in a new surprise cash charge on the 2026 balance sheet.

While clearing these investigations removes the threat of bankruptcy via regulatory fines, the combined $71.25 million paid to the SEC and class-action plaintiffs has severely depleted the company's financial reserves.

Financial Health and Balance Sheet Analysis

For clinical-stage biopharmaceutical companies with no commercialized products, cash is the ultimate metric of survival. Let’s look at the financial position of Filana Therapeutics as of its latest Q1 2026 earnings reports.

• Cash Reserves: As of September 30, 2025, the company reported $106.1 million in cash and cash equivalents. By the end of 2025, cash reserves were estimated to be in the range of $92 million to $96 million.
• Cost-Cutting Measures: The silver lining of terminating the massive Phase 3 Alzheimer's program is a drastic reduction in research and development (R&D) expenses. R&D spending fell from $69.6 million in 2024 to an estimated $26.6 million in 2025. In Q3 2025, R&D expenses were just $4.0 million, a 78% decline year-over-year as the clinical operations for Alzheimer's and SavaDx (their experimental diagnostic tool) were phased out.
• Runway Projection: Management expects its current cash runway to support operations into 2027. However, this runway assumes a highly conservative spending model. If the FDA clinical hold is lifted and Filana begins enrolling patients for the TSC-related epilepsy trial, R&D expenses will inevitably rise again.
• Capital Dilution Risk: Filana has an active shelf registration statement (Form S-3) filed in late 2025, allowing the company to raise up to $200 million through primary offerings, including an at-the-market (ATM) program of up to $50 million in common stock. If cash levels drop below a critical threshold, investors should brace for significant dilution as the company issues new shares of FLNA stock to fund its operations.

SAVA Stock / FLNA Stock Forecast and Investment Outlook

So, is sava stock (now FLNA) a buy?

To evaluate this speculative asset, we must look at the technical and fundamental realities:

• Analyst Consensus: Wall Street has largely abandoned the stock. The consensus recommendation among the very few analysts still covering the ticker is a "Hold" or "Sell," with a 12-month average price target hovering around $1.50 to $2.00, reflecting very limited upside from current levels of ~$1.31.
• The Bear Case: FLNA stock is a classic "falling knife." The core product, simufilam, already failed spectacularly in its primary indication (Alzheimer's). Transitioning a failed Alzheimer's molecule to rare epilepsy is an extremely low-probability bet. Furthermore, the FDA's clinical hold indicates deep regulatory skepticism. Investors must be prepared for the very real possibility of a total loss of capital.
• The Bull Case: If the FDA lifts the clinical hold in late 2026 and the company initiates its proof-of-concept study in TSC-related epilepsy, positive early-stage human data could spark a dramatic short-squeeze and clinical rally. With the regulatory overhang (DOJ/SEC) completely resolved, the stock is no longer weighed down by the threat of criminal indictments.
• The Verdict: FLNA is an ultra-high-risk speculative gamble, not an investment. If you are a retail investor seeking stable biotech growth, look elsewhere. If you are an aggressive speculator comfortable with extreme volatility and the potential of losing 100% of your position, FLNA represents an intriguing, albeit highly dangerous, lottery ticket.

Frequently Asked Questions (FAQ)

What happened to SAVA stock?

SAVA stock officially rebranded as Filana Therapeutics, Inc. and changed its Nasdaq ticker symbol to FLNA effective March 11, 2026. This rebrand reflects the company's shift away from its failed Alzheimer's drug trials to target rare epilepsy.

Why did the Alzheimer's trial fail?

In late 2024, the Phase 3 RETHINK-ALZ clinical trial failed to meet any of its primary, secondary, or biomarker endpoints. Cognitive and functional outcomes for patients taking simufilam were no better than those taking a placebo.

Is the DOJ investigation into Cassava Sciences over?

Yes. On February 19, 2026, the Department of Justice closed its criminal inquiry into research misconduct allegations against Cassava Sciences, ending all federal investigations into the company.

What is the current price of FLNA (formerly SAVA) stock?

As of May 2026, the stock trades as FLNA on the Nasdaq at approximately $1.31 per share, down significantly from its all-time high of $135.30 in 2021.

Is Filana Therapeutics' epilepsy drug approved?

No. Simufilam is still an investigational drug. In fact, its proposed epilepsy trial is currently on a full clinical hold by the FDA, pending further preclinical safety data.